Connect to other sites within the UBM Medica Network
Metformin May Not Improve Pancreatic Cancer Survival
Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.
MRI Screening for Individuals at High Risk for Pancreatic Cancer
An MRI screening program for individuals at high risk for pancreatic cancer may be effective, according to the results of a short-term study.
Tarextumab Gets FDA Orphan Drug Designation for Lung, Pancreatic Cancer
The US Food and Drug Administration has granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and small-cell lung cancer.
NAPOLI-1: MM-398 Combo Shows Benefit in Metastatic Pancreatic Cancer
Combining MM-398 with 5-FU/leucovorin chemotherapy in metastatic pancreatic cancer patients resulted in improved survival compared with 5-FU/leucovorin alone.
FDA Approves Lanreotide Injection for GEP-NETs
The US Food and Drug Administration approved lanreotide for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
Long-Term Diabetes Shortens Pancreatic Cancer Survival
Pancreatic cancer patients with long-standing diabetes have poorer survival than those without diabetes, according to an analysis of a pair of studies.
Initial Treatment of Well-Differentiated Neuroendocrine Tumors
In patients with advanced, unresectable NETs, there are several treatment options; which of these may be considered depends on the site of origin of the tumor.
By clicking Accept, you agree to become a member of the UBM Medica Community.